You are here

Home » Content

FORMULATION AND EVALUATION OF AMBROXOL HYDROCHLORIDE SUSTAINED RELEASE TABLET

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2012

Key Words:

Author Name
Abstract (2. Language): 
The objective of the study was to develop matrix tablets of Ambroxol Hydrochloride for Sustained Release. Hydroxy Propyl Methyl Cellulose (HPMC) K4M and Guar Gum as the retardant polymers and study the effect of various formulation factors such as polymer proportion, polymer type and e ffect of filler type on the in vitro release of the drug. Matrix tablets were prepared by wet granulation method and prepared tablets were evaluated for weight variation, friability, hardness, thickness and in vitro dissolution studies. All the granules of formulations showed compliance with pharmacopieal standards. In vitro release studies revealed that the release rate decreased with increase polymer proportion and hydrophobic polymers retard the drug release more than hydrophilic polymers. The formulations F7 sustained release of drug for 12 hrs with 91.56%. Because of swelling property increa sed the drug release profile to a small extent due to change in swelling at the tablet surface. The kinetic treatment showed that the mechanism of drug release. The developed sustained release matrix tablets of Ambroxol Hydrochloride up to 12 hrs can overcome the disadvantages of conventional tablets.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-formulation-and-evaluation-ambroxol-hydrochloride-sustained-release-tablet.pdf
  • 2
  • English

REFERENCES

References: 

1.
Chie
n YW: Novel drug delivery systems. In: Chein Oral Drug Delivery Systems. New York, Marcel Dekker: 1992; 1-5: 139-146.
2.
Bara
r FSK: In Essential of
rd
Pharmaceutics, 3 edition. New Delhi, Chand S & Company Ltd. 2003; 550.
3. Tripathi KD: Drug for Cough and Bronchial Asthma. In, Tripathi KD. Essential of Medical Pharmacology, 5th edition. New Delhi, Jaypee Brothers Medical Publisher (P) Ltd. 2004; 196.
4.
India
n Pharmacopoeia. Government of India, New Delhi: Controller of
Publications. 2007; 2: 83-4.
5. Mandal U, Gowda V, Ghosh A, Selvan
5, Solomon S, Pal T. Formulation And Optimization Of Sustained Release Matrix
Tablet Of Metformine HCl 500 Mg Using
Response Surface Methodology. YAKUGAKU ZASSHI. 2007; 127: 1281¬1290.
6. Jain S, Yadav SK, Patil UK.
Preparation and Evaluation of Sustained Release Matrix Tablet of Using Natural Polymers. Research J. Pharm. and Tech. 2008; 1(4): 374-376
7. Wells J. Pharmaceutical Preformulation: The Physical Properties of Drug Substances. In, Aulton M.E (edr). Pharmaceutics the Sciences of Dosage Form Design, 2nd edition. London, Churchill Livingstone. 2002; 133-4.
8. Sinko PJ. Martin's physical pharmacy and pharmaceutical sciences, 5th edition. Lippincott Williams and Wilkins. 2006:
557-8.
9. Fiese EF, Hagen TA. Preformulation. In, Lachman L, Lieberman AH, Kanig LJ (edrs). The Theory and Practice of Industrial Pharmacy, 3rd edition. Mumbai, Varghese Publication House. 1991; 182-4.
10. Banker GS, Anderson NR, Lachman L, Lieberman AH, Kanig LJ (edrs). The Theory and Practice of Industrial Pharmacy, 3rd edition. Mumbai, Varghese
Publication House. 1991; 296- 9.
11.
India
n Pharmacopoeia. Government of India, New Delhi: Controller of Publications. 2007; 1: 183 84.
12. Yeole PG, Galatte UC, Babla BI,
Nakhat PD. Design and Evaluation Of Xanthan Gum-based Sustained Release Matrix Tablet of Diclofenac Sodium.
Indian J Pharm. Sci. 2009; 68; 185-9.13. Chaudhari P, Chaudhari S, Barhate N,
Mistry C and Kolsure P: Design and Evaluation floating tablets of Tizanidine Hydrochloride. Indian J. Pharm. Educ.
Res. 2008; 42: 36-43.
14. Indian Pharmacopoeia. Government of India, New Delhi: Controller of
Publications, 2007; 2: 83-84.
15. Dincer Z, Basan H and Goger NG: Quantitative determination of ambroxol in tablets by derivative UV spectrophotometric method and HPLC. J.
Pharm. and Biomed. Anal. 2003; 31: 867¬872.
16. Basak SC, Reddy J and Mani L: Formulation and Release behaviour of sustained release Ambroxol Hydrochloride HPMC matrix tablet. Indian J. Pharma.
Sci. 2006; 68: 594-8.
17. Nie K, Li X, Chen J. Monitoring Ambroxol Hydrochloride Sustained-Release Tablets Release Nilesh V. Ingle.
Int. J. PharmTech Res.2011, 3(1) 313
b
y Fiber-Optic Drug Dissolution In Situ Test System. J. Dissolution Technologies.
2009: 14-7.
18. Yoshioka S and Stella VJ: Stability of
drug and dosage form. New York, Kluwer academic publishers. 2002; 223-224.
19. Chow SC: Stability Testing for
Dissolution. In, Chow SC (edr). Statistical design and analysis of stability studies, New York, Taylor and Francis. 2007; 4¬10.
20. Schwartz JB: Optimization Techniques in Pharmaceutical Formulation and Processing, In, Banker S and Rhodes CT, (edrs). Modern pharmaceutics, New
York, Marcel Dekker. 1990; 803-23.
21. ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products Q1A (R2). Current step 4 version. 2003; 3: 8.
Available Online

Thank you for copying data from http://www.arastirmax.com